REVISION HISTORY. Rev. Rev. Date Submitted by Description of Changes Reason for changes [***] [***] [***] [***] [***] [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Title: [***] Requirement Document RQ-0015 Rev. B Page 1 of 5 Rev. date: 5/24/10 Issue date: 5/27/10 Effective date: 5/27/10 Approved by/date: 5/27/10 [***] Author Approved by/date: 5/27/10 [***] Supervisor
REVISION HISTORY. Rev. No. Change Request Date Author Description
REVISION HISTORY. Draft Date Revised Items 0.1 3/2/2014 Initial draft, based on CFP4 Baseline Design, Revision P 0.2 6/28/2014 2nd draft, based on revised CFP4 Baseline Design, Revision R. Some editorial errors were corrected in Rev.R Added description on Pin-out definition.
REVISION HISTORY. Version # Details Date
REVISION HISTORY. This Memorandum of Understanding (MOU) shall be reviewed and, if necessary, revised at least annually by the Continuum of Care. See Section 6.6 of the Santa Xxxxxxx County HMIS Administrative Policies and Procedures for more details on changes of this and other documents. Date Author Description 11/30/2013 Community Technology Alliance (xxx.XXXxxxxx.xxx) New document referencing all HUD standards and 2011 HEARTH HMIS Proposed Rule 10/20/2017 HomeBase and Santa Xxxxxxx County Update documents to reflect best practices and community usage.
REVISION HISTORY. Version Date Description of Revision 1.0 07/27/2016 RTU Specifications Requirements for Customer Facility.
REVISION HISTORY. This is the first issuance of the Quality Agreement.
REVISION HISTORY. Revision Date Revision Approval (Reliant) Revision Approval (Patheon) Revision Description 2/6/04 See below See below New Agreement Reliant Pharmaceuticals Approval Patheon Pharmaceuticals, Inc. Approval Signature/Date Signature/Date XXXXXXXX X XXXXXXX XXXXXX XXXXXXXXX , 0000 Reliant Pharmaceuticals, LLC 000 Xxxxx Xxxx Liberty Corner, NJ U.S.A. 07938 Attention: Dear : Re: Capital Expenditure for Commercial Manufacture of DynaCirc CR Reliant Pharmaceuticals, LLC (“RELIANT”), and Patheon Pharmaceuticals Inc. (“Patheon”) have entered into a Manufacturing Services Agreement dated March , 2004 (the “MSA”) whereby Patheon agreed, among other things, to provide certain manufacturing services (the “Services”) with respect to DynaCirc CR (the “Product”). In order for Patheon to perform the Services, certain capital equipment will be provided by RELIANT and installed at Patheon’s Cincinnati Operations facility (the “Facility”). As well, certain modifications will be made to the Facility to accommodate such equipment. The purpose of this Letter Agreement is to set out the parties’ mutual agreement with respect to the equipment and capital expenditures required under the MSA.
REVISION HISTORY. This service information letter has had nine revision(s) as shown in Table 16. Table 16. Revision History Revision Number Revision Date 0 2 Aug 2016 1 5 Dec 2016 2 9 Apr 2018 3 10 Dec 2019 4 17 Apr 2020 5 9 Sep 2020 6 6 Nov 2020 7 27 Aug 2021 8 8 Apr 2022
REVISION HISTORY. Revision 3: Sep 01 Minor amendments to existing revision; reference to Grade 1 removed. Revision 2: Jun 01 This RMS was revised to include only Grade 1-sponge requirements. Revision 1: Feb 98 Original issue. Exhibit B-2 to Exhibit 99.1 SPECIFICATIONS FOR STANDARD GRADE SPONGE TIMET RAW MATERIAL SPECIFICATION 72.8 (REV. 1)
